{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:38:52Z","timestamp":1792723132895,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["No. ZR2023QH082"],"award-info":[{"award-number":["No. ZR2023QH082"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023YQ067"],"award-info":[{"award-number":["ZR2023YQ067"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360518"],"award-info":[{"award-number":["82360518"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-02216-5","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:05:55Z","timestamp":1785164755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding the endothelin-1 network: molecular drivers of ovarian cancer malignancy and new therapeutic horizons"],"prefix":"10.1186","volume":"19","author":[{"given":"Renhua","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dehong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"2216_CR1","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1002\/cncr.11345","volume":"97","author":"VW Chen","year":"2003","unstructured":"Chen VW, Ruiz B, Killeen JL, Cot\u00e9 TR, Wu XC, Correa CN. Pathology and classification of ovarian tumors. Cancer. 2003;97:2631\u201342.","journal-title":"Cancer"},{"key":"2216_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.apsb.2015.07.005","volume":"5","author":"X Guan","year":"2015","unstructured":"Guan X. Cancer metastases: challenges and opportunities. Acta Pharm Sin B. 2015;5:402\u201318.","journal-title":"Acta Pharm Sin B"},{"key":"2216_CR3","first-page":"69","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69\u201390.","journal-title":"CA Cancer J Clin"},{"key":"2216_CR4","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2216_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","volume":"34","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2023","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, Ray-Coquard I, Tan DSP, Bellet E, Oaknin A, Ledermann JA. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:833\u201348.","journal-title":"Ann Oncol"},{"key":"2216_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1046\/j.1440-1681.1999.03014.x","volume":"26","author":"RG Goldie","year":"1999","unstructured":"Goldie RG. Endothelins in health and disease: an overview. Clin Exp Pharmacol Physiol. 1999;26:145\u20138.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2216_CR7","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1593\/neo.06388","volume":"8","author":"A Akhavan","year":"2006","unstructured":"Akhavan A, Mchugh KH, Guruli G, Bies RR, Zamboni WC, Strychor SA, Nelson JB, Pflug BR. Endothelin receptor a blockade enhances taxane effects in prostate cancer. Neoplasia. 2006;8:725\u201332.","journal-title":"Neoplasia"},{"key":"2216_CR8","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0026-895X(24)12115-3","volume":"61","author":"D Del Bufalo","year":"2002","unstructured":"Del Bufalo D, Di Castro V, Biroccio A, Varmi M, Salani D, Rosan\u00f2 L, Trisciuoglio D, Spinella F, Bagnato A. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol. 2002;61:524\u201332.","journal-title":"Mol Pharmacol"},{"key":"2216_CR9","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/labinvest.3780178","volume":"80","author":"G Egidy","year":"2000","unstructured":"Egidy G, Eberl LP, Valdenaire O, Irmler M, Majdi R, Diserens AC, Fontana A, Janzer RC, Pinet F, Juillerat-Jeanneret L. The endothelin system in human glioblastoma. Lab Invest. 2000;80:1681\u20139.","journal-title":"Lab Invest"},{"key":"2216_CR10","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/0006-291X(90)91146-J","volume":"168","author":"K Ohnaka","year":"1990","unstructured":"Ohnaka K, Takayanagi R, Yamauchi T, Okazaki H, Ohashi M, Umeda F, Nawata H. Identification and characterization of endothelin converting activity in cultured bovine endothelial cells. Biochem Biophys Res Commun. 1990;168:1128\u201336.","journal-title":"Biochem Biophys Res Commun"},{"issue":"Suppl 5","key":"2216_CR11","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/00005344-198900135-00005","volume":"13","author":"M Yanagisawa","year":"1989","unstructured":"Yanagisawa M, Inoue A, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. The human preproendothelin-1 gene: possible regulation by endothelial phosphoinositide turnover signaling. J Cardiovasc Pharmacol. 1989;13(Suppl 5):S13\u201317. discussion S18.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2216_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/0092-8674(94)90425-1","volume":"78","author":"D Xu","year":"1994","unstructured":"Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, Dewit D, Yanagisawa M. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 1994;78:473\u201385.","journal-title":"Cell"},{"key":"2216_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/0014-5793(95)00249-9","volume":"362","author":"JB Denault","year":"1995","unstructured":"Denault JB, Claing A, D\u2019orl\u00e9ans-Juste P, Sawamura T, Kido T, Masaki T, Leduc R. Processing of proendothelin-1 by human furin convertase. FEBS Lett. 1995;362:276\u201380.","journal-title":"FEBS Lett"},{"key":"2216_CR14","doi-asserted-by":"publisher","first-page":"15262","DOI":"10.1074\/jbc.270.25.15262","volume":"270","author":"N Emoto","year":"1995","unstructured":"Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem. 1995;270:15262\u20138.","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"2216_CR15","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/00005344-199800001-00006","volume":"31","author":"T Kido","year":"1998","unstructured":"Kido T, Sawamura T, Masaki T. The processing pathway of endothelin-1 production. J Cardiovasc Pharmacol. 1998;31(Suppl 1):S13\u201315.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2216_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.lfs.2012.05.010","volume":"91","author":"C Ko","year":"2012","unstructured":"Ko C, Meidan R, Bridges PJ. Why two endothelins and two receptors for ovulation and luteal regulation? Life Sci. 2012;91:501\u20136.","journal-title":"Life Sci"},{"key":"2216_CR17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1124\/pr.54.2.219","volume":"54","author":"AP Davenport","year":"2002","unstructured":"Davenport AP. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev. 2002;54:219\u201326.","journal-title":"Pharmacol Rev"},{"key":"2216_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.tips.2004.02.008","volume":"25","author":"T Masaki","year":"2004","unstructured":"Masaki T. Historical review: Endothelin. Trends Pharmacol Sci. 2004;25:219\u201324.","journal-title":"Trends Pharmacol Sci"},{"key":"2216_CR19","first-page":"4122","volume":"82","author":"R Mancina","year":"1997","unstructured":"Mancina R, Barni T, Calogero AE, Filippi S, Amerini S, Peri A, Susini T, Vannelli GB, Burrello N, Forti G, Maggi M. Identification, characterization, and biological activity of endothelin receptors in human ovary. J Clin Endocrinol Metab. 1997;82:4122\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"2216_CR20","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1093\/humrep\/der066","volume":"26","author":"DH Choi","year":"2011","unstructured":"Choi DH, Kim EK, Kim KH, Lee KA, Kang DW, Kim HY, Bridges P, Ko C. Expression pattern of endothelin system components and localization of smooth muscle cells in the human pre-ovulatory follicle. Hum Reprod. 2011;26:1171\u201380.","journal-title":"Hum Reprod"},{"key":"2216_CR21","first-page":"720","volume":"59","author":"A Bagnato","year":"1999","unstructured":"Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra MR, Venuti A, Natali PG. Expression of endothelin 1 and endothelin a receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res. 1999;59:720\u20137.","journal-title":"Cancer Res"},{"key":"2216_CR22","first-page":"1059","volume":"1","author":"A Bagnato","year":"1995","unstructured":"Bagnato A, Tecce R, Moretti C, Di Castro V, Spergel D, Catt KJ. Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res. 1995;1:1059\u201366.","journal-title":"Clin Cancer Res"},{"key":"2216_CR23","first-page":"1306","volume":"57","author":"A Bagnato","year":"1997","unstructured":"Bagnato A, Tecce R, Di Castro V, Catt KJ. Activation of mitogenic signaling by endothelin 1 in ovarian carcinoma cells. Cancer Res. 1997;57:1306\u201311.","journal-title":"Cancer Res"},{"key":"2216_CR24","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/S0959-8049(99)00131-8","volume":"35","author":"S Moraitis","year":"1999","unstructured":"Moraitis S, Miller WR, Smyth JF, Langdon SP. Paracrine regulation of ovarian cancer by endothelin. Eur J Cancer. 1999;35:1381\u20137.","journal-title":"Eur J Cancer"},{"key":"2216_CR25","doi-asserted-by":"publisher","first-page":"7084","DOI":"10.1038\/sj.onc.1208857","volume":"24","author":"M Kamrava","year":"2005","unstructured":"Kamrava M, Simpkins F, Alejandro E, Michener C, Meltzer E, Kohn EC. Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer. Oncogene. 2005;24:7084\u201393.","journal-title":"Oncogene"},{"key":"2216_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/0196-9781(93)90057-N","volume":"14","author":"B Battistini","year":"1993","unstructured":"Battistini B, Chailler P, D\u2019orl\u00e9ans-Juste P, Bri\u00e8re N, Sirois P. Growth regulatory properties of endothelins. Peptides. 1993;14:385\u201399.","journal-title":"Peptides"},{"key":"2216_CR27","first-page":"5310","volume":"60","author":"F Vacca","year":"2000","unstructured":"Vacca F, Bagnato A, Catt KJ, Tecce R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res. 2000;60:5310\u20137.","journal-title":"Cancer Res"},{"key":"2216_CR28","doi-asserted-by":"publisher","first-page":"27850","DOI":"10.1074\/jbc.M202421200","volume":"277","author":"F Spinella","year":"2002","unstructured":"Spinella F, Rosan\u00f2 L, Di Castro V, Natali PG, Bagnato A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem. 2002;277:27850\u20135.","journal-title":"J Biol Chem"},{"key":"2216_CR29","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.lfs.2012.03.033","volume":"91","author":"E Garrafa","year":"2012","unstructured":"Garrafa E, Caprara V, Di Castro V, Rosan\u00f2 L, Bagnato A, Spinella F. Endothelin-1 cooperates with hypoxia to induce vascular-like structures through vascular endothelial growth factor-C, -D and -A in lymphatic endothelial cells. Life Sci. 2012;91:638\u201343.","journal-title":"Life Sci"},{"key":"2216_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","volume":"5","author":"M Markman","year":"2000","unstructured":"Markman M, Bookman MA. Second-line treatment of ovarian cancer. Oncologist. 2000;5:26\u201335.","journal-title":"Oncologist"},{"key":"2216_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1242\/jcs.115.3.455","volume":"115","author":"LM Luttrell","year":"2002","unstructured":"Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci. 2002;115:455\u201365.","journal-title":"J Cell Sci"},{"key":"2216_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13046-016-0401-4","volume":"35","author":"L Rosan\u00f2","year":"2016","unstructured":"Rosan\u00f2 L, Bagnato A. \u03b2-arrestin1 at the cross-road of endothelin-1 signaling in cancer. J Exp Clin Cancer Res. 2016;35:121.","journal-title":"J Exp Clin Cancer Res"},{"key":"2216_CR33","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.lfs.2012.03.023","volume":"91","author":"R Cianfrocca","year":"2012","unstructured":"Cianfrocca R, Tocci P, Spinella F, Di Castro V, Bagnato A, Rosan\u00f2 L. The endothelin a receptor and epidermal growth factor receptor signaling converge on \u03b2-catenin to promote ovarian cancer metastasis. Life Sci. 2012;91:550\u20136.","journal-title":"Life Sci"},{"key":"2216_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.lfs.2014.01.078","volume":"118","author":"R Cianfrocca","year":"2014","unstructured":"Cianfrocca R, Tocci P, Semprucci E, Spinella F, Di Castro V, Bagnato A, Rosan\u00f2 L. \u03b2-Arrestin 1 is required for endothelin-1-induced NF-\u03baB activation in ovarian cancer cells. Life Sci. 2014;118:179\u201384.","journal-title":"Life Sci"},{"key":"2216_CR35","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrm3141","volume":"12","author":"DA Murphy","year":"2011","unstructured":"Murphy DA, Courtneidge SA. The \u2018ins\u2019 and \u2018outs\u2019 of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol. 2011;12:413\u201326.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2216_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1146\/annurev.cellbio.21.020604.150721","volume":"21","author":"AB Jaffe","year":"2005","unstructured":"Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247\u201369.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"2216_CR37","doi-asserted-by":"publisher","first-page":"e29846","DOI":"10.4161\/sgtp.29846","volume":"5","author":"L Julian","year":"2014","unstructured":"Julian L, Olson MF. Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions. Small GTPases. 2014;5:e29846.","journal-title":"Small GTPases"},{"key":"2216_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.lfs.2016.01.008","volume":"159","author":"P Tocci","year":"2016","unstructured":"Tocci P, Caprara V, Cianfrocca R, Sestito R, Di Castro V, Bagnato A, Rosan\u00f2 L. Endothelin-1\/endothelin a receptor axis activates RhoA GTPase in epithelial ovarian cancer. Life Sci. 2016;159:49\u201354.","journal-title":"Life Sci"},{"key":"2216_CR39","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1038\/onc.2015.403","volume":"35","author":"E Semprucci","year":"2016","unstructured":"Semprucci E, Tocci P, Cianfrocca R, Sestito R, Caprara V, Veglione M, Castro VD, Spadaro F, Ferrandina G, Bagnato A, Rosan\u00f2 L. Endothelin A receptor drives invadopodia function and cell motility through the \u03b2-arrestin\/PDZ-RhoGEF pathway in ovarian carcinoma. Oncogene. 2016;35:3432\u201342.","journal-title":"Oncogene"},{"key":"2216_CR40","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1073\/pnas.1715998115","volume":"115","author":"F Di Modugno","year":"2018","unstructured":"Di Modugno F, Caprara V, Chellini L, Tocci P, Spadaro F, Ferrandina G, Sacconi A, Blandino G, Nistic\u00f2 P, Bagnato A, Rosan\u00f2 L. hMENA is a key regulator in endothelin-1\/\u03b2-arrestin1-induced invadopodial function and metastatic process. Proc Natl Acad Sci U S A. 2018;115:3132\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2216_CR41","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.matbio.2018.10.005","volume":"81","author":"L Chellini","year":"2019","unstructured":"Chellini L, Caprara V, Spadaro F, Sestito R, Bagnato A, Rosan\u00f2 L. Regulation of extracellular matrix degradation and metastatic spread by IQGAP1 through endothelin-1 receptor signalling in ovarian cancer. Matrix Biol. 2019;81:17\u201333.","journal-title":"Matrix Biol"},{"key":"2216_CR42","doi-asserted-by":"crossref","unstructured":"Tocci P, Caprara V, Roman C, Sestito R, Rosan\u00f2 L, Bagnato A. YAP signaling orchestrates the endothelin-1-guided invadopodia formation in high-grade serous ovarian cancer. Biosci Rep. 2024;44:BSR20241320.","DOI":"10.1042\/BSR20241320"},{"key":"2216_CR43","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"2216_CR44","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2216_CR45","doi-asserted-by":"publisher","first-page":"11649","DOI":"10.1158\/0008-5472.CAN-05-2123","volume":"65","author":"L Rosan\u00f2","year":"2005","unstructured":"Rosan\u00f2 L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, De Herreros AG, Natali PG, Bagnato A. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res. 2005;65:11649\u201357.","journal-title":"Cancer Res"},{"key":"2216_CR46","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13046-022-02317-1","volume":"41","author":"R Sestito","year":"2022","unstructured":"Sestito R, Tocci P, Roman C, Di Castro V, Bagnato A. Functional interaction between endothelin-1 and ZEB1\/YAP signaling regulates cellular plasticity and metastasis in high-grade serous ovarian cancer. J Exp Clin Cancer Res. 2022;41:157.","journal-title":"J Exp Clin Cancer Res"},{"key":"2216_CR47","doi-asserted-by":"publisher","first-page":"101160","DOI":"10.1016\/j.tranon.2021.101160","volume":"14","author":"M Cheng","year":"2021","unstructured":"Cheng M, Ye X, Dai J, Sun F. SOS1 promotes epithelial-mesenchymal transition of Epithelial Ovarian Cancer(EOC) cells through AKT independent NF-\u03baB signaling pathway. Transl Oncol. 2021;14:101160.","journal-title":"Transl Oncol"},{"key":"2216_CR48","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1158\/1541-7786.MCR-10-0386","volume":"9","author":"T Yu","year":"2011","unstructured":"Yu T, Wu Y, Helman JI, Wen Y, Wang C, Li L. CXCR4 promotes oral squamous cell carcinoma migration and invasion through inducing expression of MMP-9 and MMP-13 via the ERK signaling pathway. Mol Cancer Res. 2011;9:161\u201372.","journal-title":"Mol Cancer Res"},{"key":"2216_CR49","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/path.4586","volume":"237","author":"GT Brown","year":"2015","unstructured":"Brown GT, Murray GI. Current mechanistic insights into the roles of matrix metalloproteinases in tumour invasion and metastasis. J Pathol. 2015;237:273\u201381.","journal-title":"J Pathol"},{"key":"2216_CR50","first-page":"8340","volume":"61","author":"L Rosan\u00f2","year":"2001","unstructured":"Rosan\u00f2 L, Varmi M, Salani D, Di Castro V, Spinella F, Natali PG, Bagnato A. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res. 2001;61:8340\u20136.","journal-title":"Cancer Res"},{"key":"2216_CR51","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1158\/1535-7163.MCT-05-0523","volume":"5","author":"L Rosan\u00f2","year":"2006","unstructured":"Rosan\u00f2 L, Spinella F, Di Castro V, Dedhar S, Nicotra MR, Natali PG, Bagnato A. Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Mol Cancer Ther. 2006;5:833\u201342.","journal-title":"Mol Cancer Ther"},{"key":"2216_CR52","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1038\/s41467-019-12930-y","volume":"10","author":"R Ferrari","year":"2019","unstructured":"Ferrari R, Martin G, Tagit O, Guichard A, Cambi A, Voituriez R, Vassilopoulos S, Chavrier P. MT1-MMP directs force-producing proteolytic contacts that drive tumor cell invasion. Nat Commun. 2019;10:4886.","journal-title":"Nat Commun"},{"key":"2216_CR53","doi-asserted-by":"publisher","first-page":"21968","DOI":"10.18632\/oncotarget.7880","volume":"7","author":"L Bruney","year":"2016","unstructured":"Bruney L, Liu Y, Grisoli A, Ravosa MJ, Stack MS. Integrin-linked kinase activity modulates the pro-metastatic behavior of ovarian cancer cells. Oncotarget. 2016;7:21968\u201381.","journal-title":"Oncotarget"},{"key":"2216_CR54","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3892\/or.2012.2148","volume":"29","author":"W Zhang","year":"2013","unstructured":"Zhang W, Ling D, Tan J, Zhang J, Li L. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance. Oncol Rep. 2013;29:637\u201345.","journal-title":"Oncol Rep"},{"key":"2216_CR55","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/1476-4598-10-130","volume":"10","author":"H Raghu","year":"2011","unstructured":"Raghu H, Gondi CS, Dinh DH, Gujrati M, Rao JS. Specific knockdown of uPA\/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch\u2009\u2013\u20091 receptor. Mol Cancer. 2011;10:130.","journal-title":"Mol Cancer"},{"key":"2216_CR56","doi-asserted-by":"publisher","first-page":"m3773","DOI":"10.1136\/bmj.m3773","volume":"371","author":"L Kuroki","year":"2020","unstructured":"Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773.","journal-title":"BMJ"},{"key":"2216_CR57","doi-asserted-by":"publisher","first-page":"7453","DOI":"10.1158\/0008-5472.CAN-13-3133","volume":"74","author":"L Rosan\u00f2","year":"2014","unstructured":"Rosan\u00f2 L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG, Bagnato A. Endothelin A receptor\/\u03b2-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy. Cancer Res. 2014;74:7453\u201364.","journal-title":"Cancer Res"},{"key":"2216_CR58","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nrc3546","volume":"13","author":"L Rosan\u00f2","year":"2013","unstructured":"Rosan\u00f2 L, Spinella F, Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2013;13:637\u201351.","journal-title":"Nat Rev Cancer"},{"key":"2216_CR59","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.canlet.2020.08.026","volume":"492","author":"P Tocci","year":"2020","unstructured":"Tocci P, Cianfrocca R, Sestito R, Rosan\u00f2 L, Di Castro V, Blandino G, Bagnato A. Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer. Cancer Lett. 2020;492:84\u201395.","journal-title":"Cancer Lett"},{"key":"2216_CR60","doi-asserted-by":"publisher","first-page":"24187","DOI":"10.3390\/ijms141224187","volume":"14","author":"S Chen","year":"2013","unstructured":"Chen S, Wang J, Gou WF, Xiu YL, Zheng HC, Zong ZH, Takano Y, Zhao Y. The involvement of RhoA and Wnt-5a in the tumorigenesis and progression of ovarian epithelial carcinoma. Int J Mol Sci. 2013;14:24187\u201399.","journal-title":"Int J Mol Sci"},{"key":"2216_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4161\/cbt.13.1.18440","volume":"13","author":"T Ohta","year":"2012","unstructured":"Ohta T, Takahashi T, Shibuya T, Amita M, Henmi N, Takahashi K, Kurachi H. Inhibition of the Rho\/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1\u03b1 in human ovarian cancer cells. Cancer Biol Ther. 2012;13:25\u201333.","journal-title":"Cancer Biol Ther"},{"key":"2216_CR62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41419-022-05538-6","volume":"14","author":"P Tocci","year":"2023","unstructured":"Tocci P, Roman C, Sestito R, Di Castro V, Sacconi A, Molineris I, Paolini F, Carosi M, Tonon G, Blandino G, Bagnato A. Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition. Cell Death Dis. 2023;14:5.","journal-title":"Cell Death Dis"},{"key":"2216_CR63","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1158\/1535-7163.MCT-06-0053","volume":"5","author":"F Spinella","year":"2006","unstructured":"Spinella F, Rosan\u00f2 L, Di Castro V, Decandia S, Albini A, Nicotra MR, Natali PG, Bagnato A. Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol Cancer Ther. 2006;5:1483\u201392.","journal-title":"Mol Cancer Ther"},{"key":"2216_CR64","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1158\/1078-0432.CCR-04-2395","volume":"11","author":"H Kajiyama","year":"2005","unstructured":"Kajiyama H, Shibata K, Terauchi M, Morita T, Ino K, Mizutani S, Kikkawa F. Neutral endopeptidase 24.11\/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo. Clin Cancer Res. 2005;11:1798\u2013808.","journal-title":"Clin Cancer Res"},{"key":"2216_CR65","doi-asserted-by":"publisher","first-page":"9265","DOI":"10.1158\/0008-5472.CAN-08-2093","volume":"68","author":"O Rayhman","year":"2008","unstructured":"Rayhman O, Klipper E, Muller L, Davidson B, Reich R, Meidan R. Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. Cancer Res. 2008;68:9265\u201373.","journal-title":"Cancer Res"},{"issue":"Suppl 48","key":"2216_CR66","doi-asserted-by":"publisher","first-page":"s318","DOI":"10.1042\/CS103S318S","volume":"103","author":"D Salani","year":"2002","unstructured":"Salani D, Rosan\u00f2 L, Di Castro V, Spinella F, Venuti A, Padley RJ, Nicotra MR, Natali PG, Bagnato A. ABT-627, a potent endothelin receptor a antagonist, inhibits ovarian carcinoma growth in vitro. Clin Sci (Lond). 2002;103(Suppl 48):s318\u201321.","journal-title":"Clin Sci (Lond)"},{"key":"2216_CR67","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-07-0151","volume":"6","author":"L Rosan\u00f2","year":"2007","unstructured":"Rosan\u00f2 L, Di Castro V, Spinella F, Nicotra MR, Natali PG, Bagnato A. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther. 2007;6:2003\u201311.","journal-title":"Mol Cancer Ther"},{"key":"2216_CR68","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/CAD.0b013e328320791c","volume":"20","author":"JW Growcott","year":"2009","unstructured":"Growcott JW. Preclinical anticancer activity of the specific endothelin a receptor antagonist ZD4054. Anticancer Drugs. 2009;20:83\u20138.","journal-title":"Anticancer Drugs"},{"key":"2216_CR69","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.lfs.2016.01.009","volume":"159","author":"R Sestito","year":"2016","unstructured":"Sestito R, Cianfrocca R, Rosan\u00f2 L, Tocci P, Di Castro V, Caprara V, Bagnato A. Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis. Life Sci. 2016;159:43\u20138.","journal-title":"Life Sci"},{"key":"2216_CR70","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.1158\/0008-5472.CAN-07-0883","volume":"67","author":"L Rosan\u00f2","year":"2007","unstructured":"Rosan\u00f2 L, Di Castro V, Spinella F, Tortora G, Nicotra MR, Natali PG, Bagnato A. Combined targeting of endothelin a receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res. 2007;67:6351\u20139.","journal-title":"Cancer Res"},{"key":"2216_CR71","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1593\/neo.10582","volume":"12","author":"PO Witteveen","year":"2010","unstructured":"Witteveen PO, Van Der Mijn KJ, Los M, Kronemeijer RH, Groenewegen G, Voest EE. Phase 1\/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. Neoplasia. 2010;12:941\u20135.","journal-title":"Neoplasia"},{"key":"2216_CR72","first-page":"2447","volume":"63","author":"L Rosan\u00f2","year":"2003","unstructured":"Rosan\u00f2 L, Spinella F, Salani D, Di Castro V, Venuti A, Nicotra MR, Natali PG, Bagnato A. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res. 2003;63:2447\u201353.","journal-title":"Cancer Res"},{"key":"2216_CR73","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1139\/Y10-053","volume":"88","author":"L Rosan\u00f2","year":"2010","unstructured":"Rosan\u00f2 L, Cianfrocca R, Spinella F, Di Castro V, Natali PG, Bagnato A. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer. Can J Physiol Pharmacol. 2010;88:676\u201381.","journal-title":"Can J Physiol Pharmacol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02216-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02216-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-02216-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:02:05Z","timestamp":1792720925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-02216-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2216"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-02216-5","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. Registry and the Registration No. of the study\/trial: N\/A. Animal Studies: N\/A.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"323"}}